Condition
HPV 16 Positive Oropharyngeal Tumors (OPC)
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting1
Unknown1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07209189Phase 2Recruiting
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
NCT07418034Phase 2Not Yet Recruiting
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
NCT06097936Unknown
New Prognostic and Predictive Biomarkers for HPV-associated Oropharyngeal Cancer
Showing all 3 trials